Fluorescence-based DNA sequencing has been used to decipher the functional importance of DNA polymorphisms and mutations. One gene that has received recent attention is the class I ␤-tubulin isotype M40. Mutations have been identified in M40, which accounts for more than 85% of total ␤-tubulin RNA in cell lines used in the National Cancer Institute anti-cancer drug screen and in 12 human tumor xenografts (1) . Using four overlapping sets of primers (GenBank accession number J00314), two mutations-a Phe 270 Val and an Ala 364 Thrwere identified in M40 from paclitaxelresistant human ovarian cancer cells (1A9PTX10 and 1A9PTX22, respectively) (2) . Recently, when sequencing complementary DNA (cDNA) with similar primers, a heterozygous Leu mutation was identified in vincristineresistant CCRF-CEM human lymphoblastic T-cell leukemia cells (3) . Furthermore, cDNA from Chinese hamster lung tumor cells was sequenced for several ␣-and ␤-tubulin isotypes, and multiple nucleotide changes located outside the open reading frame were identified (4) .
Using the one-dye labeled primer method for the ALFexpress sequencer (thermo sequenase fluorescent labeled primer cycle sequencing kit with 7-deazadGTP, Amersham Pharmacia, Uppsala, Sweden), we analyzed genomic DNA from 49 non-small-cell lung cancer (NSCLC) patients. We detected numerous heterozygous single nucleotide substitutions in the phosphate, ribose, and base regions of the ␤-tubulin exon 4 GTP-binding site [see Fig. 1 and Table 2 of our original article (5)].
In their interesting article, Kelley et al. (6) describe a worst-case scenario with negative data on ␤-tubulin mutations. The authors state that they "were unable to examine the base-binding region because the published sequence of oligonucleotide TB4-R is not present in TUBB." The TB4 reverse primer shown in our original article (5) was written incorrectly. The correct reading should be 5Ј-TGAGGTCCGGCACTGTGAG-3Ј (GenBank accession number J00314); however, the latest sequence from GenBank (GenBank accession number AC006165) is now correct and shows that one nucleotide of this primer sequence has changed and reads 5Ј-TGAGTTCCGGCACTGTGAG-3Ј (changed nucleotide shown in bold).
One of the major limitations in the study by Kelley et al. (6) seems to be that they scanned a small region of exon 4 that did not include the base-binding region where we found ␤-tubulin mutations [see Fig. 1 and Table 1 ). However, except for these changes, none of the mutations from our original study (5) were pseudogenes. In a later study (7), we used a primer pair (forward primer 5Ј-AAGAAGATACATCCGAGGGA-ATTAT-3Ј from intronic position 2901 and a reverse primer 5Ј-GGCAGTTGAG-TAAGACGGCTAA-3Ј from exonic position 4117) (GenBank accession number AC006165) to obtain a polymerase chain reaction (PCR) product of 1216 base pairs, which encompasses the entire exon 4, a region much larger than that described by Kelley et al. By fluorescence-based sequencing of PCR products, we detected multiple heterozygous single nucleotide substitutions in genomic serum DNA from 131 patients with NSCLC (7). However, on checking the sequences in BLAST (www.ncbi. nlm.nih.gov/blast), we found that a number of these substitutions corresponded to pseudogenes, including a Val-Ile change detected in four patients.
We concede that the originally identified sequence for M40 may contain some errors. In fact, basing our work on GenBank J00314, where the codon 11 sequence is CAA, we had identified a CAA (Gln) to CAG (Gln) polymorphism at amino acid 11 of M40 in all of 131 serum DNA samples (7). However, the new database (GenBank AC006165, cDNA NM_001069) identifies this supposed variant (CAG) as the normal sequence.
Because the presence of pseudogenes could not be completely ruled out at the time of our original study, the relationship between mutations and survival remains unclear. On the basis of the findings by Kelley et al. (6) , we cannot rule out the possibility that some of the mutations represent rare nonpathogenic variants. Conflicting data on ␤-tubulin research should be elucidated by sequencing cDNA, obviating the cumbersome worst-case scenario of pseudogenes. (M40)  ACC  GTG  GTC  GAG  CCC  TAC  AAT  GCC  AC006165  ACC  GTG  GTC  GAG  CCC  TAC  AAT  GCC  HUMTBB14P †  ACC  GTG  GTT  GAG  CCC  TAC  AAT  GCC  HUMTBB46Q †  ACC  GTG  ATC  GAG  TCC  TAC  AAT  GCT  HSTUB1 †  ACC  GTG  ACC  GAG  TCC  TAC  AAT  GCT  HUMTBB46P †  ACC  GTG  ATC  GAG  TCC  TAC  AAT  GCT  HUMTBB21P †  ACC  GTG  ATC  GAG  TCC  TAC  AAT  GCT  HUMBTUB67 †  ACC  GTG  GTC  GAG  CCC  TAC  AAC  ATC  HUMTBB7P †  ACC  GTG  GTC  GAG  CCC  TAC Recently, Kelley et al. (1) reported that there were no amino-acid-altering mutations in the class I ␤-tubulin (also known as M40 or TUBB) among 25 lung cancer cell lines and 20 primary non-small-cell lung cancers (NSCLCs). This result contrasts with a report by Monzo et al. (2) that 33% of 49 NSCLC samples harbored mutations in the ␤-tubulin gene and were "a strong predictor of the response to the antitubulin drug paclitaxel."
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We have recently reported strong conservation of the class I ␤-tubulin gene among human populations and an absence of mutations of this gene in ovarian and lung cancers (3). DNA was isolated from 93 control individuals representing a wide variety of ethnicities and from 79 cancer specimens or human tumor cell lines. There were 62 specimens derived from ovarian carcinomas, including 32 without prior exposure to paclitaxel, and 30 known paclitaxelresistant specimens. We also included 17 nontreated NSCLC specimens. We screened for sequence variations in exons 1, 2, 3, the first half of exon 4, and flanking noncoding regions of human class I ␤-tubulin by using denaturing high pressure liquid chromatography (DHPLC). The second half of exon 4 was analyzed by direct sequence analysis because the 3Ј-UTR region contains a run of G's that cause slippage and, consequently, formation of heteroduplexes that may affect the ability of DHPLC to detect mutations.
None of the 172 tumor samples, cell lines, xenografts, or controls had nonsynonymous (i.e., amino acid altering) mutations or polymorphisms in the coding region. We detected two silent polymorphisms in exon 4-Leu 217 Leu (CTG/ CTA) and Gly 400 Gly (GGC/GGT)-with minor allele frequencies of 17% and 0.5%, respectively. The amino acid sequence of class I ␤-tubulin was completely conserved among chimpanzee, orangutan, gorilla, and humans. Nucleotide diversity analysis revealed that human class I ␤-tubulin is one of the most conserved genes studied so far, with 4.4-fold less sequence diversity than that found in 106 other human genes (4) .
What are the reasons for the discrepancies between the study by Monzo et al. (2) and the reports by Kelley et al. (1) and our group (3)? Specificity of the primers is one of the crucial issues in the analysis of single nucleotide polymorphisms and mutations in any gene, particularly those with more than one isotype or with pseudogenes. Sequence variations in ␤-tubulin are especially difficult to study because there are six ␤-tubulin isotypes and more than 20 ␤-tubulin pseudogenes, all of which are highly homologous.
In analyzing class I ␤-tubulin, Monzo et al. (2) designed primers TP4 and STP4, which have 100% identity not only for class I ␤-tubulin but also for four ␤-tubulin pseudogenes (GenBank accession numbers V00598, K00841, J00317, and M24191). Moreover, another primer for exon 4, STB4, does not have a 100% match with any gene, including class I ␤-tubulin. The closest match is located on chromosome 16 and is not specific for the whole primer sequence. Lack of specificity for the class I ␤-tubulin isotype could have resulted in a mixture of polymerase chain reaction (PCR) products and a false-positive detection of mutations. Kelley et al. (1) provide experimental evidence supporting this hypothesis. We used the class I ␤-tubulin sequence retrievable from GenBank (accession number J00314) to design five pairs of primers encompassing all exons, adjacent intronic sequences, and 5Ј-and 3Ј-UTRs and to test amplicon specificity (Fig. 1) .
The paper of Monzo et al. (3) . EnF, forward primer; EnR, reverse primer (n ‫ס‬ 1-4). Two pairs of primers were used to amplify exon 4. (Fig. reproduced from (3) with permission from American Association for Cancer Research.)
